Advertisement
| refusing hormone therapy for breast cancer premenopausal: Probably Someday Cancer Kim Horner, 2019-02-15 After learning that she inherited a BRCA2 genetic mutation that put her at high risk for breast and ovarian cancer, Kim Horner’s doctors urged her to consider having a double mastectomy. But how do you decide whether to have a surgery to remove your breasts to reduce your risk for a disease you don’t have and may never get? Horner shares her struggle to answer that question in Probably Someday Cancer. The mother of a one-year-old boy, she wanted to do whatever would give her the best odds of being around for her son and protect her from breast cancer, which killed her grandmother and great-grandmother in their 40s. Which would give her the best chance at a long healthy life: a double mastectomy or frequent screenings to try to catch any cancer early? The answers weren’t that simple. Based on extensive research, interviews, and personal experience, Horner writes about how and why she ultimately opted for a double mastectomy—the same decision actress Angelina Jolie made for a similar genetic mutation—and the surprising diagnosis that followed. The book explores difficult truths that get overshadowed by upbeat messages about early detection and survivorship—the fact that screenings can miss cancers and that even early-stage breast cancers can spread and become fatal. Probably Someday Cancer is about the author’s efforts to push past her fear and anxiety. This book can help anyone facing hereditary risk of breast and ovarian cancer feel less alone and make informed decisions to protect their health and end the devastation that hereditary cancer has caused for generations in so many families. |
| refusing hormone therapy for breast cancer premenopausal: Breast Cancer Task Force Program and Related Projects , 1981 |
| refusing hormone therapy for breast cancer premenopausal: Compilation of Cancer Therapy Protocol Summaries International Cancer Research Data Bank, 1980 |
| refusing hormone therapy for breast cancer premenopausal: Compilation of Cancer Therapy Protocol Summaries , 1980 Detailed outlines of ongoing experimental clinical trials. Data may also be retrieved in CLINPROT. Classified arrangement according to site. Each entry gives such information as investigator and address, objective, protocol outline, and dosage schedule. Tumor, agent, and protocol organizational number indexes. Miscellaneous appendixes. |
| refusing hormone therapy for breast cancer premenopausal: Menopausing: The positive roadmap to your second spring Davina McCall, Dr. Naomi Potter, 2022-09-15 Winner of The British Book Awards 2023 Overall Book of the Year‘We can’t wait for this.’ RedMenopausing is more than just a book, it’s a movement. An uprising. |
| refusing hormone therapy for breast cancer premenopausal: AJCC Cancer Staging Manual Frederick L, Greene, David L. Page, Irvin D. Fleming, April G. Fritz, Charles M. Balch, Daniel G. Haller, Monica Morrow, 2013-11-21 The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms. |
| refusing hormone therapy for breast cancer premenopausal: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| refusing hormone therapy for breast cancer premenopausal: Journal of the National Cancer Institute , 2013 |
| refusing hormone therapy for breast cancer premenopausal: Oncoplastic and Reconstructive Surgery for Breast Cancer A. Fitoussi, M. G. Berry, B. Couturaud, R. J. Salmon, 2009-06-19 Oncoplastic and Reconstructive Surgery for Breast Cancer describes the reconstructive techniques that have been refined over the past decade by surgeons in a very high volume unit. It provides clear descriptions of all the available techniques. With proven experience in the procedures described and detailed scientific evaluation, it furthermore provides evidence-based literature reviews. The book starts with the relevant anatomical background and passes through all the major oncoplastic and reconstructive procedures available to the breast cancer patient. It includes management of breast and nipple-areolar complex reconstruction in addition to symmetrising surgery and the new technique of fat transfer. It also covers all multidisciplinary aspects and genetics thus giving an up-to-date status report. |
| refusing hormone therapy for breast cancer premenopausal: Clinical Breast Imaging Gilda Cardenosa, 2006-11-01 Prepared by a preeminent breast imaging expert, this case-based teaching file atlas presents a clinically oriented approach to screening, diagnostic evaluation, and management of patients with breast conditions encountered by radiologists. Dr. Cardeñosa takes the reader through more than 170 actual patient cases, from classic Aunt Minnies to more complex and controversial problems in screening, diagnostic evaluation, and patient management. Cases are thoroughly illustrated with clear, sharp images—over 800 images total—and include multiple imaging studies, pathology studies, and pathologic correlations where appropriate. Emphasis is on determining the clinical significance of abnormalities or potential abnormalities detected on images. |
| refusing hormone therapy for breast cancer premenopausal: Oncologic Therapies Everett E. Vokes, Harvey M. Golomb, 2002-11-21 This second edition has been updated in a user-friendly layout that makes its comprehensive information extremely accessible. The handbook, written for all physicians who treat cancer patients, provides a survey of current therapeutic concepts of solid tumors and hematologic malignancies in internal oncology. Each individual chapter of this shortened new edition is structured in the same way and features a brief outline or tabular summary of the main aspects of epidemiology, pathology, staging, and diagnosis. The main focus is on the therapeutic strategy, i.e., an interdisciplinary approach to systemic drug therapy. Surgical and radiological concepts of treatment are also covered, as are supportive care, pain relief methods and ethical problems. This title is a must for clinicians and practitioners as well as interns, residents and postgraduate students. |
| refusing hormone therapy for breast cancer premenopausal: Geriatric Emergency Medicine Joseph H. Kahn, Brendan G. Magauran (Jr.), Jonathan S. Olshaker, 2014-01-16 This comprehensive volume provides a practical framework for evaluation, management and disposition of this growing vulnerable patient population. |
| refusing hormone therapy for breast cancer premenopausal: The Health Benefits of Smoking Cessation United States. Public Health Service. Office of the Surgeon General, 1990 |
| refusing hormone therapy for breast cancer premenopausal: Reversal of Aging Walter Pierpaoli, 2005 The body of research on the process of human aging has grown considerably in recent years, and the reports presented here explore a full range of approaches to this research, from the molecular and genetic to the cellular and organismic levels. The contributing scientists identify the processes of aging and find functional and mechanistic approaches that may delay, prevent, or arrest the progress of aging and those ailments generally linked to senescence, such as metabolic, cardiovascular, and autoimmune diseases. The investigation of various approaches to the prevention of aging will include efforts to mitigate the deleterious consequences of chemical pollution. |
| refusing hormone therapy for breast cancer premenopausal: Essential Psychiatry Robin M. Murray, Kenneth S. Kendler, Peter McGuffin, Simon Wessely, David J. Castle, 2008-09-18 This is a major international textbook for psychiatrists and other professionals working in the field of mental healthcare. With contributions from opinion-leaders from around the globe, this book will appeal to those in training as well as to those further along the career path seeking a comprehensive and up-to-date overview of effective clinical practice backed by research evidence. The book is divided into cohesive sections moving from coverage of the tools and skills of the trade, through descriptions of the major psychiatric disorders and on to consider special topics and issues surrounding service organization. The final important section provides a comprehensive review of treatments covering all of the major modalities. Previously established as the Essentials of Postgraduate Psychiatry, this new and completely revised edition is the only book to provide this depth and breadth of coverage in an accessible, yet authoritative manner. |
| refusing hormone therapy for breast cancer premenopausal: Endometriosis Pathogenesis, Clinical Impact and Management Andrea R. Genazzani, Michelle Nisolle, Felice Petraglia, Robert N. Taylor, 2020-12-07 This volume focuses on endometriosis from its pathogenesis and the importance of the early diagnosis to treatment, throughout all aspects of femininity that this disease affects, impacting health and quality of life. It also covers treatment strategies for the pain and for the disease management according to the age and needs of the patient, from adolescence to menopause, passing through the fertile age and the consequences that this disease can have on fertility and pregnancy. This book is a useful, clear and up-to-date tool for gynecologists, gynecological surgeons, reproductive medicine and general practitioners and is an important source of information to face this more and more frequent and devastating disease. |
| refusing hormone therapy for breast cancer premenopausal: Handbook of Diversity Issues in Health Psychology Pamela M. Kato, Traci Mann, 2007-07-27 The field of health psychology has grown dramatically in the last decade, with exciting new developments in the study of how psychological and psychosocial processes contribute to risk for and disease sequelae for a variety of medical problems. In addition, the quality and effectiveness of many of our treatments, and health promotion and disease prevention efforts, have been significantly enhanced by the contributions of health psychologists (Taylor, 1995). Unfortunately, however, much of the theo rizing in health psychology and the empirical research that derives from it continue to reflect the mainstream bias of psychology and medicine, both of which have a primary focus on white, heterosexual, middle-class American men. This bias pervades our thinking despite the demographic heterogeneity of American society (U. S. Bureau of the Census, 1992) and the substantial body of epidemiologic evidence that indicates significant group differences in health status, burden of morbidity and mortality, life expectancy, quality of life, and the risk and protective factors that con tribute to these differences in health outcomes (National Center for Health Statistics, 1994; Myers, Kagawa-Singer, Kumanyika, Lex, & M- kides, 1995). There is also substantial evidence that many of the health promotion and disease prevention efforts that have proven effective with more affluent, educated whites, on whom they were developed, may not yield comparable results when used with populations that differ by eth nicity, social class, gender, or sexual orientation (Cochran & Mays, 1991; Castro, Coe, Gutierres, & Saenz, this volume; Chesney & Nealey, this volume). |
| refusing hormone therapy for breast cancer premenopausal: Essentials of Clinical Radiation Oncology Matthew C. Ward, MD, Rahul D. Tendulkar, MD, Gregory M. M. Videtic, MD, CM, FRCPC, 2017-12-28 Essentials of Clinical Radiation Oncology is a comprehensive, user-friendly clinical review that summarizes up-to-date cancer care in an easy-to-read format. Each chapter is structured for straightforward navigability and information retention beginning with a “quick-hit” summary that contains an overview of each disease, its natural history, and general treatment options. Following each quick-hit are high-yield summaries covering epidemiology, risk factors, anatomy, pathology, genetics, screening, clinical presentation, workup, prognostic factors, staging, treatment paradigms, and medical management for each malignancy. Each treatment paradigm section describes the current standard of care for radiation therapy including indications, dose constraints, and side effects. Chapters conclude with an evidence-based question and answer section which summarizes practice-changing data to answer key information associated with radiation treatment outcomes. Flow diagrams and tables consolidate information throughout the book that all radiation oncologists and related practitioners will find extremely useful when approaching treatment planning and clinical care. Essentials of Clinical Radiation Oncology has been designed to replicate a house manual created and used by residents in training and is a one-stop resource for practicing radiation oncologists, related practitioners, and radiation oncology residents entering the field. Key Features: Offers digestible information as a learning guide for general practice Examines essential clinical questions which are answered with evidence-based data from important clinical studies Places clinical trials and data into historical context and points out relevance in current practice Provides quick reference tables on treatment options and patient selection, workup, and prognostic factors by disease site |
| refusing hormone therapy for breast cancer premenopausal: European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis European Commission. Directorate-General for Health and Consumer Protection, Nicholas Perry, 2006 Breast cancer is the most frequent cause of cancer-related deaths in women in Europe, and demographic trends indicate a continuing increase in this substantial public health problem. Systematic early detection through screening, effective diagnostic pathways and optimal treatment have the ability to substantially lower current breast cancer mortality rates and reduce the burden of this disease in the population. This is the fourth edition of these guidelines which contains information on recommended standards and procedures for breast cancer screening and diagnostic services, including chapters on multi-disciplinary aspects of quality assurance, data collection and monitoring, effective communication of information, requirements of a specialist unit, and a certification protocol. |
| refusing hormone therapy for breast cancer premenopausal: Hormones and Breast Cancer in Post-Menopausal Women Sandra Z. Haslam, Janet R. Osuch, 2006 Focuses on the challenges of determining the mechanistic basis for the role of hormones in the etiology of postmenopausal breast cancer. This book intends to bring attention to the advancements and challenges facing effective prevention and treatment of this disease. |
| refusing hormone therapy for breast cancer premenopausal: Anti-ageing Medicine Astrid Stuckelberger, 2008 The 21st century technological development is revolutionizing medicine and health care, bringing new hopes to human suffering by offering cures and treatments which were unthinkable a few decades ago. This is where anti-ageing medicine finds its niche. Anti-ageing medicine aims at slowing, arresting, and reversing phenomena associated with ageing by merging biotechnological innovation and engineered solutions. Ideally, by means of the newest medical technology, the body machinery should be kept fit and at peak performance all life long. Early detection of age-related dysfunction should thus be fixed at any age with interventions such as metabolic fine tuning, enhancement, regeneration, restoration or replacement of body parts (i.e. organs, skin, bone or muscle). It covers a vast array of domains: from cell therapy to pharmaceutical interventions, from bio-surgery to aesthetic surgery, from human enhancement to fortified food, from smart housing and robots to toxic-free environments. Anti-ageing medicine holds promises but also significant risks and safety issues which are addressesd in this book. It presents the latest scientific evidence on what works or does not work. It also provides public policy recommendations to ensure the protection of consumers and their rights while encouraging research and development. This book is intended for academics, health professionals, business persons, consumers and policy-makers interested in the latest evidence and ethical issues about anti-ageing medicine. |
| refusing hormone therapy for breast cancer premenopausal: Breast Cancer Anna M. Maslin, Trevor J. Powles, 1999 Of all cancers, probably breast cancer is one of the most emotive. Increasingly patients with breast cancer are participating in the surgical and/or medical decisions about their treatment. This involvement raises ethical issues about the rights of patients and their ability to give an informed consent, concerns about the process of communication between the medical staff and the patient, and also issues about the psychology of not only the woman with breast cancer, but also the doctor. This book addresses these issues relating to shared decision making and in particular those areas where a choice of treatment option involves some degree of risk/benefit analysis. It covers the ethical principles and then looks at the evidence that women who are fully informed and who have taken part in the decision making process regarding their treatment, and who have a positive attitude towards their illness, tend to do better in the long run. Appropriate experts have contributed sections on the different treatment options to provide a brief overview of the treatments available and highlight the issues that should be considered by the woman and the doctor in the decision making process. There is also a section on the patients perspective and vignettes throughout to illustrate the importance of communication. |
| refusing hormone therapy for breast cancer premenopausal: Encyclopedia of Health Psychology Alan J. Christensen, René Martin, Joshua Morrison Smyth, 2014-01-16 - Not only is Health Psychology, a field that focuses on the promotion and maintenance of both physical and mental health, a rapidly growing area of interest, but it is also a field that draws on and contributes to the other varied fields of psychology, medicine, nursing, sociology, anthropology, among others. - Provides a relatively comprehensive and accesible overview of the central concepts, issues, conditions and terms that comprise the broad discipline of health psychology - Covers more than 200 contributions by more than 150 of the leading researchers, educators, and practitioners in the field |
| refusing hormone therapy for breast cancer premenopausal: The Hormone Myth Robyn Stein DeLuca, 2017-08 “The Hormone Myth is a bracing, accurate breath of fresh air. It turns conventional wisdom about hormones on its head, and provides a far more liberating view of women’s health than what we’ve all been taught.” —Christiane Northrup, MD, author of Women's Bodies, Women's Wisdom “Is it that time of month?” “Is your biological clock ticking?” You're so emotional lately—are you going through menopause? We’ve all heard it before. From the moody menstrual monster to the menopausal maniac, the idea that women become raving lunatics when their hormones fluctuate is firmly entrenched in American culture—anddeeply fueled by the media. But where exactly did this stereotype come from? How has it hurt women? And how can we move past it once and for all? In this breakthrough book, Robyn Stein DeLuca fearlessly exposes and debunks pervasive myths about women’s hormones, and reveals how flawed, outdated research and sexism have joined forces throughout history to keep women “in their place.” With a revolutionary exploration of women’s hormonal lives—from menstruation to childbirth to menopause—DeLuca shines a much-needed light on the lies that have impacted women. Now more than ever, it’s time to resist the myth that women are ruled by their hormones. It’s time for women to take charge of their lives. And it’s time for women to own their emotions in a healthy and realistic way. |
| refusing hormone therapy for breast cancer premenopausal: Estrogen Matters Carol Tavris, Avrum Bluming, 2018-09-04 A compelling, “fascinating” (Robert Cialdini) defense of hormone replacement therapy, exposing the faulty science behind its fall from prominence and giving women the evidence they need to make informed decisions about their health. Now fully revised and updated. Estrogen Matters was my antidote to the misinformation surrounding menopause. This book should be the bible for every single person going through menopause.”―Naomi Watts For years, hormone replacement therapy (HRT) was the medically approved way to alleviate menopausal symptoms (ranging from hot flushes to brain fog) and reduce the risk of heart disease, Alzheimer's, and osteoporosis. But when a large study by the Women's Health Initiative (WHI) announced, with national fanfare, that women taking HRT had an increased risk of breast cancer, women were scared off, and the treatment was abandoned. Now, Dr. Bluming, a medical oncologist, and Dr. Tavris, a social psychologist, reveal the true story of the WHI’s efforts to distort their data to exaggerate unsupported claims of estrogen’s harms. Important updates in this edition include: Evidence that demolishes the WHI’s claim that HRT causes breast cancer. A list of the WHI’s retractions of their original scare stories. Updated findings on estrogen’s benefits on heart, brain, bones, and longevity. A critical review of the alternative products and medications being marketed to treat symptoms of menopause. A sobering and revelatory read, Estrogen Matters sets the record straight on estrogen’s benefits, providing a light to guide women through this inevitable phase of life. |
| refusing hormone therapy for breast cancer premenopausal: Respiratory Endoscopy Takehiro Izumo, Shinji Sasada, Tomohiko Aso, Kazuko Nasu, Yasuaki Arai, 2016-11-08 This book provides a detailed overview of the latest innovations in respiratory endoscopy, from both diagnostic and therapeutic perspectives; each chapter focuses on one disease and the techniques for early diagnosis as well as treatment. It comprehensively covers treatment and procedures, including simultaneous X-ray fluoroscopy and its use during bronchoscopic procedures. This fast-developing technology is essential for the medical management of non-malignant and malignant diseases of the chest, especially lung cancer. Respiratory Endoscopy describes the cooperation between all the members of the healthcare team, and as such is a valuable resource not only for medical staff, but also for radiological technicians and nursing staff who contribute significantly in the care of the patients undergoing these invasive procedures. By promoting teamwork and providing practical know-how, it will improve the success and safety of respiratory endoscopy procedures. |
| refusing hormone therapy for breast cancer premenopausal: The Science and Practice of Lithium Therapy Gin S. Malhi, Marc Masson, Frank Bellivier, 2016-11-24 This book provides a clear and comprehensive guide to the clinical prescription of lithium that draws upon evidence-based knowledge of its mechanisms of action. The book is divided into two parts, on the science of lithium and the practice of lithium therapy. The former covers aspects such as the properties of the lithium ion, pharmacokinetics and pharmacodynamics, impact on neurotransmission, and gene expression modulation. The section on practice includes discussion of variability in response to lithium, use of lithium in the treatment of bipolar disorders, its value in suicide prevention, administration during pregnancy and in the pediatric age group, and side effects. Lithium is arguably the only true mood stabilizer, and its multifaceted effects across many clinical domains have given rise to a resurgence of interest in recent years, fuelled by both researchers and clinicians. Nevertheless, its use remains constrained by exaggerated concerns about potential side-effects. In reality, lithium is a simple molecule that is relatively straightforward to administer and monitor and has potentially profound benefits at a fraction of the cost of contemporary agents. This book dispels the many myths and concerns that surround its use and will be of interest for clinicians and researchers worldwide, and those that are recipients of lithium therapy. |
| refusing hormone therapy for breast cancer premenopausal: Estrogen's Storm Season Jerilynn C. Prior, |
| refusing hormone therapy for breast cancer premenopausal: Endocrine Disrupting Chemicals-induced Metabolic Disorders and Treatment Strategies Muhammad Sajid Hamid Akash, Kanwal Rehman, Muhammad Zaffar Hashmi, 2021-08-06 This volume offers a detailed and comprehensive analysis of Endocrine Disrupting Chemicals (EDCs), covering their occurrence, exposure to humans and the mechanisms that lead to the parthogenesis of EDCs-induced metabolic disorders. The book is divided into three parts. Part I describes the physiology of the human endocrine system, with special emphasis on various types of metabolic disorders along with risk factors that are responsible for the development of these disorders. Part II addresses all aspects of EDCs, including their role in the induction of various risk factors that are responsible for the development of metabolic disorders. Part III covers up-to-date environmental regulatory considerations and treatment strategies that have been adopted to cure and prevent EDCs-induced metabolic disorders. This section will primarily appeal to clinicians investigating the causes and treatment of metabolic disorders. The text will also be of interest to students and researchers in the fields of Environmental Pharmacology and Toxicology, Environmental Pollution, Pharmaceutical Biochemistry, Biotechnology, and Drug Metabolism/Pharmacokinetics. |
| refusing hormone therapy for breast cancer premenopausal: European Guidelines for Quality Assurance in Mammography Screening Nicholas Perry, J. Schouten, 2001 The benefits of a screening programme for breast cancer are early detection and the subsequent reduction of mortality. The potential disadvantages are unnecessary anxiety, inappropriate economic cost and the use of ionising radiation. To ensure that the benefits outweigh the disadvantages the whole screening system needs to be completely quality assured. These European guidelines are based on the experience gained through national screening programmes. It contains information that can be applied at all levels and improvements can be achieved by following the technical advice. This third edition has been revised in the light of further experience over the past four years. |
| refusing hormone therapy for breast cancer premenopausal: Weight Management Hubertus Himmerich, 2020-09-09 Weight management is a multi- and cross-disciplinary challenge. This book covers many etiological and diagnostic aspects of weight-related disorders and their treatment. This book explains how body weight influences and is influenced by the brain, hormones and immune system, diet, physical activity, posture and gait, and the social environment. This book also elucidates the health consequences of significantly low or pathologically increased body weight. Furthermore, ideas on how to influence and manage body weight including anti-obesity medical devices, diet counselling, artificial sweeteners, prebiotics and probiotics, proanthocyanidins, bariatric surgery, microbiota transplantation, warming, physical exercise, music and psychological therapy are discussed. |
| refusing hormone therapy for breast cancer premenopausal: LGBTQ Cultures Michele J. Eliason, Peggy L. Chinn, 2017-10-16 Drawn from real-world experience and current research, the fully updated LGBTQ Cultures, 3rd Edition paves the way for healthcare professionals to provide well-informed, culturally sensitive healthcare to lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients. This vital guide fills the LGBTQ awareness gaps, including replacing myths and stereotypes with facts, and measuring the effects of social stigma on health. Vital for all nursing specialties, this is the seminal guide to actively providing appropriate, culturally sensitive care to persons of all sexual orientations and gender identities. |
| refusing hormone therapy for breast cancer premenopausal: Sentinel Lymph Node Biopsy Hiram S. Cody, 2001-11-08 An intuitive, ingenious and powerful technique, sentinel lymph node biopsy has entered clinical practice with astonishing rapidity and now represents a new standard of care for melanoma and breast cancer patients, while showing great promise for the treatment of urologic, colorectal, gynecologic, and head and neck cancers. This text, written by international experts in the technique, provides a clear and comprehensive guide, presenting a detailed overview and discussing the various mapping techniques available and how these are applied in a number of leading institutions. This essential resource for surgical onocologists, pathologists, and specialists in nuclear medicine will also provide key information for those planning to start a sentinel lymph node program. |
| refusing hormone therapy for breast cancer premenopausal: Transgender Medicine Leonid Poretsky, Wylie C. Hembree, 2019-02-22 Although transgender persons have been present in various societies throughout human history, it is only during the last several years that they have become widely acknowledged in our society and their right to quality medical care has been established. In the United States, endocrinologists have been providing hormonal therapy for transgender individuals for decades; however, until recently, there has been only limited literature on this subject, and non-endocrine aspects of medical care for transgender individual have not been well addressed in the endocrine literature. The goal of this volume is not only to address the latest in hormonal therapy for transgender individuals (including pediatric and geriatric age groups), but also to familiarize the reader with other aspects of transgender care, including primary and surgical care, fertility preservation, and the management of HIV infection. In addition to medical issues, psychological, social, ethical and legal issues pertinent to transgender individuals add to the complexities of successful treatment of these patients. A final chapter includes extensive additional resources for both transgender patients and providers. Thus, an endocrinologist providing care to a transgender person will be able to use this single resource to address most of the patient’s needs. While Transgender Medicine is intended primarily for endocrinologists, this book will be also useful to primary care physicians, surgeons providing gender-confirming procedures, mental health professionals participating in the care of transgender persons, and medical residents and students. |
| refusing hormone therapy for breast cancer premenopausal: Health Behavior Karen Glanz, Barbara K. Rimer, K. Viswanath, 2015-07-27 The essential health behavior text, updated with the latest theories, research, and issues Health Behavior: Theory, Research and Practice provides a thorough introduction to understanding and changing health behavior, core tenets of the public health role. Covering theory, applications, and research, this comprehensive book has become the gold standard of health behavior texts. This new fifth edition has been updated to reflect the most recent changes in the public health field with a focus on health behavior, including coverage of the intersection of health and community, culture, and communication, with detailed explanations of both established and emerging theories. Offering perspective applicable at the individual, interpersonal, group, and community levels, this essential guide provides the most complete coverage of the field to give public health students and practitioners an authoritative reference for both the theoretical and practical aspects of health behavior. A deep understanding of human behaviors is essential for effective public health and health care management. This guide provides the most complete, up-to-date information in the field, to give you a real-world understanding and the background knowledge to apply it successfully. Learn how e-health and social media factor into health communication Explore the link between culture and health, and the importance of community Get up to date on emerging theories of health behavior and their applications Examine the push toward evidence-based interventions, and global applications Written and edited by the leading health and social behavior theorists and researchers, Health Behavior: Theory, Research and Practice provides the information and real-world perspective that builds a solid understanding of how to analyze and improve health behaviors and health. |
| refusing hormone therapy for breast cancer premenopausal: Lippincott's Review for Medical-surgical Nursing Certification Lippincott, 2011-10-20 Lippincott's Review for Medical-Surgical Nursing Certification, Fifth Editionprovides the information nurses need to achieve certification in the specialty of medical-surgical nursing. This helpful reference covers the broad range of content found on the actual examinations, including disorders by body system, such as coronary artery disease, COPD, and diabetes. The product reviews signs and symptoms, diagnostic tests, medical treatments, nursing assessments, and interventions for scores of health problems. Concise refreshers on wound care, perioperative nursing, collaborative practice, nursing research, and legal issues are also included. Review questions after each chapter and an end-of-book posttest help assess the nurse's preparedness for the exam. The book is appropriate for exams of both major certifying bodies: the ANCC and the AMSN. |
| refusing hormone therapy for breast cancer premenopausal: Applying Quantitative Bias Analysis to Epidemiologic Data Timothy L. Lash, Matthew P. Fox, Aliza K. Fink, 2011-04-14 Bias analysis quantifies the influence of systematic error on an epidemiology study’s estimate of association. The fundamental methods of bias analysis in epi- miology have been well described for decades, yet are seldom applied in published presentations of epidemiologic research. More recent advances in bias analysis, such as probabilistic bias analysis, appear even more rarely. We suspect that there are both supply-side and demand-side explanations for the scarcity of bias analysis. On the demand side, journal reviewers and editors seldom request that authors address systematic error aside from listing them as limitations of their particular study. This listing is often accompanied by explanations for why the limitations should not pose much concern. On the supply side, methods for bias analysis receive little attention in most epidemiology curriculums, are often scattered throughout textbooks or absent from them altogether, and cannot be implemented easily using standard statistical computing software. Our objective in this text is to reduce these supply-side barriers, with the hope that demand for quantitative bias analysis will follow. |
| refusing hormone therapy for breast cancer premenopausal: Endocrine Therapy in Breast Cancer William R. Miller, James N. Ingle, 2002-03-08 This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine T |
| refusing hormone therapy for breast cancer premenopausal: Obstetric Anesthesia Craig M. Palmer, Robert D'Angelo, Michael J. Paech, 2011-04-13 In the United States, over half of pregnant women receive some form of anesthesia for their deliveries; this translates into well over 2 million anesthetics per year. With this new handbook, anesthesiologists have easy access to step-by-step, to-the-point information on how to manage patients in specific situations. Every aspect of obstetric anesthesia practice is covered, including patient evaluation, anesthesia for labor and delivery, anesthesia for cesarean delivery, management of patients with concurrent medical problems, management of obstetric emergencies, fetal assessment, and neonatal resuscitation. Distilled, synthesized text is complemented by a generous number of tables, charts, figures and flow diagrams, all presented in accessible handbook format. Obstetric Anesthesia is an ideal introduction to the specialty as well as an essential daily guide for obstetric patient care and management. |
| refusing hormone therapy for breast cancer premenopausal: Breast Disease Adnan Aydiner, Abdullah İğci, Atilla Soran, 2019 This second updated volume on breast cancer provides a comprehensive overview of its clinical management and current therapies. Updated to reflect the changes in breast cancer staging, the progress in immunotherapy approaches, as well as the latest guidelines for therapies, this book brings readers up to speed with the latest therapeutic regimens in breast cancer and provides an in-depth account of current and new therapeutic approaches. The most important phase III trials, high quality meta-analysis, consensus reports and guidelines are extensively discussed in this new edition and provide the reader with the most up-to-date information. Divided in themed parts, the book examines invasive breast cancer, pre-operative systemic therapy surgical management and recurrence among others, thus providing an in-depth account of breast cancer at the clinical stage. Among the themed parts are a section dedicated to special therapeutic problems, such as breast cancer in older women, Paget's disease and phyllodes tumors and a section on supportive and follow-up care. By adopting a multidisciplinary approach to breast cancer, this book is a must-have for breast cancer practitioners. With a high number of colored illustrations and edited by highly experienced clinicians, this work enables readers to gain an interdisciplinary perspective on breast diseases. Contributions from an international team of experts present invaluable insight into clinical practice across different settings. Covering both theoretical and practical aspects of breast cancer, this is a highly informative and carefully presented book which will appeal to an international audience of medical, radiation and surgical oncologists. |
The benefits and risks of HRT before and after a breast cancer …
HRT exposure on pre-existing, hormone sensitive, occult breast cancers. Withdrawal of unopposed oestrogen stops o. strogen-induced apoptosis, leading to an increase in cancer …
Refusing Hormone Therapy For Breast Cancer Premenopausal
hormone-receptor–positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.... BMS & WHC’s 2020 recommendations on hormone …
The oncologic impact of hormone replacement therapy in …
Synopsis: This is the first systematic review to investigate the risk of recurrence in breast cancer sur-vivors <50 years old who have used hormone replacement therapy (HRT). Background: …
The management of estrogen deficiency symptoms, arthralgia and ...
symptoms associated with breast cancer treatment. 4. Lifestyle measures and non-hormonal interventions should be first-line management for estrogen deficiency symptoms but if these …
FAST FACTS HRT and breast cancer risk - British Menopause Society
HRT and breast cancer risk There remains controversy about the risk of breast cancer diagnosis and mor tality associated with HRT. This fact sheet summarises key findings and conclusions …
Type and timing of menopausal hormone therapy and breast …
Reliable assessment of the association between menopausal hormone therapy (MHT) use and breast cancer requires avoidance of appreciable confounding or bias, with important features …
Refusing Hormone Therapy For Breast Cancer Premenopausal …
Health interrupted their huge HRT (hormone replacement therapy) study in July 2002 after they found that Prempro, a combination of estrogen and progestin, had detrimental health effects …
Refusing Hormone Therapy For Breast Cancer Premenopausal
The hormonal therapy chapters focus on current uses of endocrine therapy in endometrial, breast, and prostate cancer. In addition, hormonal strategies for the prevention of breast cancer and
Bringing safe and effective therapies to premenopausal women …
Table 1 outlines completed key phase III and/or registration trials of endocrine-based therapies in patients with HR-positive breast cancer in the early and advanced/metastatic set-tings, the …
BREAST CANCER Challenges in Adjuvant Therapy for …
Premenopausal women with hormone receptor–positive breast cancer often present with complex disease and have inferior survival outcomes compared with their postmenopausal counterparts.
Cancer Treatment Reviews
Endocrine therapy has significantly improved clinical outcomes for premenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) …
The menopause, hormone replacement therapy and breast cancer
HRT encompasses a range of regimens, none of which mimic the premenopausal hormonal milieu and this may re-sult in differing effects on breast cancer incidence and prog-nosis.
Revisiting Adjuvant Hormone Therapy in Premenopausal Women …
The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) have published guidelines for locoregional breast cancer that suggest in …
BMS, IMS, EMAS, RCOG and AMS Joint Statement on menopausal …
The risk of breast cancer should be considered in the context of the overall benefits and risks associated with MHT intake including menopausal symptom control, improved quality of life …
Surgical ovarian suppression for adjuvant treatment in hormone …
Objective Ovarian suppression is recommended to complement endocrine therapy in premenopausal women with breast cancer and high- risk features. It can be achieved by either …
Treatment and Monitoring Patterns Among Premenopausal …
Introduction: Premenopausal women with hormone receptor positive (HR?) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (aBC) often present with …
Treatment of Premenopausal Women: Finding the Right-Sized …
with early-stage breast cancer require long-term follow-up care by dedicated professionals trained in the nuanced health risks of premenopausal cancer treatment.
Aromatase inhibitors versus tamoxifen in premenopausal women …
For premenopausal women with early-stage, ER-positive breast cancer treated with ovarian suppression, use of an aromatase inhibitor rather than tamoxifen further reduces the risk of …
Endocrine Therapy in Premenopausal Hormone Receptor–Positive …
Recent randomized trials have demonstrated a benefit for the addition of ovarian suppression to endocrine therapy in patients with breast cancers considered to be at high risk for recurrence, …
Taking tamoxifen to reduce the chance of developing breast …
This decision aid can help you to decide whether or not to take a medicine called tamoxifen to reduce your chance of developing breast cancer. It is not intended for women who have had …
The benefits and risks of HRT before and after a breast cancer …
HRT exposure on pre-existing, hormone sensitive, occult breast cancers. Withdrawal of unopposed oestrogen stops o. strogen-induced apoptosis, leading to an increase in cancer …
Refusing Hormone Therapy For Breast Cancer Premenopausal
hormone-receptor–positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.... BMS & WHC’s 2020 recommendations on hormone …
The oncologic impact of hormone replacement therapy in premenopausal ...
Synopsis: This is the first systematic review to investigate the risk of recurrence in breast cancer sur-vivors <50 years old who have used hormone replacement therapy (HRT). Background: …
The management of estrogen deficiency symptoms, arthralgia …
symptoms associated with breast cancer treatment. 4. Lifestyle measures and non-hormonal interventions should be first-line management for estrogen deficiency symptoms but if these …
FAST FACTS HRT and breast cancer risk - British Menopause …
HRT and breast cancer risk There remains controversy about the risk of breast cancer diagnosis and mor tality associated with HRT. This fact sheet summarises key findings and conclusions …
Type and timing of menopausal hormone therapy and breast cancer …
Reliable assessment of the association between menopausal hormone therapy (MHT) use and breast cancer requires avoidance of appreciable confounding or bias, with important features …
Refusing Hormone Therapy For Breast Cancer Premenopausal …
Health interrupted their huge HRT (hormone replacement therapy) study in July 2002 after they found that Prempro, a combination of estrogen and progestin, had detrimental health effects …
Refusing Hormone Therapy For Breast Cancer Premenopausal
The hormonal therapy chapters focus on current uses of endocrine therapy in endometrial, breast, and prostate cancer. In addition, hormonal strategies for the prevention of breast cancer and
Bringing safe and effective therapies to premenopausal women …
Table 1 outlines completed key phase III and/or registration trials of endocrine-based therapies in patients with HR-positive breast cancer in the early and advanced/metastatic set-tings, the …
BREAST CANCER Challenges in Adjuvant Therapy for Premenopausal …
Premenopausal women with hormone receptor–positive breast cancer often present with complex disease and have inferior survival outcomes compared with their postmenopausal counterparts.
Cancer Treatment Reviews
Endocrine therapy has significantly improved clinical outcomes for premenopausal patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) …
The menopause, hormone replacement therapy and breast cancer
HRT encompasses a range of regimens, none of which mimic the premenopausal hormonal milieu and this may re-sult in differing effects on breast cancer incidence and prog-nosis.
Revisiting Adjuvant Hormone Therapy in Premenopausal Women With Breast ...
The National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) have published guidelines for locoregional breast cancer that suggest in …
BMS, IMS, EMAS, RCOG and AMS Joint Statement on menopausal hormone
The risk of breast cancer should be considered in the context of the overall benefits and risks associated with MHT intake including menopausal symptom control, improved quality of life …
Surgical ovarian suppression for adjuvant treatment in hormone …
Objective Ovarian suppression is recommended to complement endocrine therapy in premenopausal women with breast cancer and high- risk features. It can be achieved by either …
Treatment and Monitoring Patterns Among Premenopausal …
Introduction: Premenopausal women with hormone receptor positive (HR?) and human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (aBC) often present with …
Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy
with early-stage breast cancer require long-term follow-up care by dedicated professionals trained in the nuanced health risks of premenopausal cancer treatment.
Aromatase inhibitors versus tamoxifen in premenopausal women …
For premenopausal women with early-stage, ER-positive breast cancer treated with ovarian suppression, use of an aromatase inhibitor rather than tamoxifen further reduces the risk of …
Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer
Recent randomized trials have demonstrated a benefit for the addition of ovarian suppression to endocrine therapy in patients with breast cancers considered to be at high risk for recurrence, …
Taking tamoxifen to reduce the chance of developing breast cancer …
This decision aid can help you to decide whether or not to take a medicine called tamoxifen to reduce your chance of developing breast cancer. It is not intended for women who have had …
